GO
Loading...

Enter multiple symbols separated by commas

Stocks Novartis AG

More

  • TRENTON, N.J.— Amgen Inc. shares jumped in extended trading after the maker of osteoporosis drug Prolia easily beat Wall Street's second-quarter profit expectations and hiked its 2015 financial forecast. Amgen, based in Thousand Oaks, California, said Thursday it sees strong momentum for the second half of the year, with three new drugs launching, new approvals...

  • Teva's MS drug Copaxone has strong second-quarter sales Thursday, 30 Jul 2015 | 8:42 AM ET

    JERUSALEM, July 30- Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world's biggest generic drug maker, said that global...

  • *HIV sales help offset margin slide post Novartis deal. LONDON, July 29- GlaxoSmithKline moved to reclaim its prowess as a research powerhouse on Wednesday by flagging up dozens of new drugs and vaccines in development, as demand for new HIV medicines helped it beat quarterly profit forecasts. The drugmaker recently sold its marketed cancer drugs to Novartis...

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...

  • GSK sees drop in earnings after asset swap with Novartis Wednesday, 29 Jul 2015 | 8:16 AM ET

    LONDON— Britain- based drugmaker GlaxoSmithKline has reported a drop in earnings in the first full quarter since its deal to swap some assets with Swiss rival Novartis. CEO Andrew Witty described the performance as encouraging, with plans on track to integrate and restructuring operations it took over from Novartis in April. In the deal, GSK agreed to sell its...

  • *Margins slide in first full quarter after Novartis deal. LONDON, July 29- A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less than expected 9 percent. The drugmaker recently sold its marketed cancer drugs to Novartis and...

  • New heart drugs come in more expensive than expected Monday, 27 Jul 2015 | 6:02 AM ET

    *Sanofi, Novartis set high prices for Praluent, Entresto. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. Sanofi and Regeneron, which won U.S. approval on Friday for Praluent to treat stubbornly high...

  • EAST RUTHERFORD, N.J.— A new drug for advanced basal cell carcinoma, an increasingly common cancer in the skin's top layer, has won Food and Drug Administration approval. The drug, known chemically as sonidegib, is a daily pill developed by Swiss drugmaker Novartis AG, which has U.S. pharmaceuticals headquarters in East Hanover, New Jersey. Novartis hasn't...

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • FDA approves Novartis's advanced skin cancer drug Friday, 24 Jul 2015 | 12:19 PM ET

    July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer.

  • Do your investments operate in China? Read this Friday, 24 Jul 2015 | 12:09 PM ET
    A worker repairs steam locomotive parts in Fuxin coal mine locomotive repair plant in Fuxin, China.

    From software companies to drugmakers to fast food chains, economic weakness in China is denting multinationals' financials this earnings season.

  • Novartis earnings fall, CEO focuses on heart drug Thursday, 23 Jul 2015 | 6:58 PM ET
    Joe Jimenez, CEO of Novartis, at 2015 WEF in Davos, Switzerland.

    Novartis saw sales fall in Q2, but it's optimistic about its pipeline, particularly heart disease drug Entresto, CEO Joe Jimenez says.

  • July 23- Eli Lilly and Co's quarterly sales rose for the first time in seven quarters, helped by demand for its new diabetes and cancer drugs as well as the acquisition of Novartis AG's animal health business. Lilly's net profit fell to $600.8 million, or 56 cents per share, from $733.5 million, or 68 cents per share, a year earlier. It also bumped up the lower end of its...

  • July 23- Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business. The Indianapolis- based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a...

  • Eli Lilly tops Street 2Q forecasts, raises outlook Thursday, 23 Jul 2015 | 6:36 AM ET

    NEW YORK— Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 74 cents per share. Six analysts surveyed by Zacks expected $4.84 billion in revenue.

  • *Wall Street slides with earnings in focus. Stocks on Wall Street fell, with results from bellwethers IBM and United Technologies weighing the most on the S&P 500, while Apple slumped 7 percent late after posting earnings. "For the first time in a while fundamentals seem to be driving the action today in an otherwise very quiet macro backdrop and probably will...

  • WASHINGTON— A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication. Novartis received federal approval in March to sell its cheaper copy of Amgen's Neupogen, which is used to boost blood cells in cancer patients.

  • NEW YORK, July 21- Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio, the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion- a-year anti-infection drug Neupogen, a U.S. appeals court said on Tuesday. The ruling stemmed from a lawsuit that Amgen filed last October in federal court in San Francisco in...

  • Europe stocks lose steam; earnings in focus Tuesday, 21 Jul 2015 | 11:30 AM ET
    Gold bars in Vienna, Austria

    European stocks closed lower in choppy trade on Tuesday, with investors eyeing earnings and commodity prices.

  • Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more Tuesday, 21 Jul 2015 | 8:04 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.